National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Drug Information
    Posted: 10/01/2007    Updated: 10/11/2007
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Related pages
Drug Information Summaries

Approval Process for New Cancer Treatments

Access to Investigational Drugs: Q & A
Carboplatin

This page contains brief information about carboplatin and a collection of links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM).

US Brand Name(s):Paraplatin
Paraplat
FDA Approved:Yes

Carboplatin is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat the following types of cancer:

Carboplatin is approved to be used by itself for palliative treatment of ovarian cancer that has recurred (come back) after earlier chemotherapy.

In addition to the uses that have been approved by the FDA, carboplatin is used to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Information from the NCI

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trial Results: Meta-Analysis Suggests Cisplatin Superior to Carboplatin for Advanced Non-Small Cell Lung Cancer (NSCLC) (06/19/2007) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Less-Intense Chemotherapy Effective in Children with Intermediate-Risk Neuroblastoma (06/13/2007) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Gemcitabine Plus Carboplatin Benefits Women with Recurrent Ovarian Cancer (09/27/2006) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Carboplatin May Be Less Toxic Than Radiation for Seminoma (06/07/2004) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Post-Surgery Chemotherapy Improves Survival in Early Lung Cancer (06/05/2004) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Docetaxel Plus Carboplatin a Possible Alternative for Ovarian Cancer (11/23/2004) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Paclitaxel Plus Platinum Gives Patients with Recurrent Ovarian Cancer More Time (06/25/2003) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Some Survival Benefit from Multidrug Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) (05/20/2002) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Announcement for Preferred Method of Treatment for Advanced Ovarian Cancer: Questions and Answers (01/04/2006) - Information about the use of this drug to treat cancer.

Information from the NLM

MedlinePlus Information on Carboplatin - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials

Clinical Trials for Carboplatin - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.


Back to TopBack to Top


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov